Tamoxifen

In this video, Aruna Padmanabhan, MD, discusses the effectiveness of cyclin-dependent kinase inhibitors in the treatment of metastatic hormone-positive breast cancer.

SAN ANTONIO — Tamoxifen lowered overall and invasive ipsilateral recurrence among women with “good-risk” ductal carcinoma in situ who opted for breast conservation surgery without radiation.

In this video interview, Sara M. Tolaney, MD, MPH, highlights the efficacy of low-dose tamoxifen used for breast cancer prevention.

Jack Cuzick, PhD, received the William L. McGuire Memorial Lecture Award at this year’s San Antonio Breast Cancer Symposium.

Persistent chemotherapy-related amenorrhea was common and associated with worse long-term quality of life for premenopausal women with breast cancer, according to findings published in JAMA Network Open.

Treatment with a vaginal tamoxifen capsule in postmenopausal women with moderate to severe vulvovaginal atrophy was safe with minimal drug exposure, researchers reported in a phase 1/2 clinical study.

SAN ANTONIO — Use of low-dose tamoxifen conferred a sustained reduction in risk for recurrence among women with noninvasive breast cancer, according to updated results from the randomized, phase 3 TAM-01 trial.

Tamoxifen use in the treatment of breast cancer was associated with greater risks for endometrial cancer, hyperplasia and polyps, as well as other uterine cancers among premenopausal women in Korea, according to study data.

Endocrine therapies have revolutionized the field of breast cancer, with significant improvements in survival outcomes among patients with hormone receptor-positive disease.

Use of an aromatase inhibitor instead of tamoxifen reduced the risk for breast cancer recurrence among premenopausal women with ER-positive disease who received ovarian suppression, according to a study published in The Lancet Oncology.